8-K: Calidi Biotherapeutics Announces $5.1 Million At-The-Market Offering

Calidi Biotherapeutics has entered into an agreement to sell up to $5.1 million of its common stock through an at-the-market offering.

Summary

• Calidi Biotherapeutics has entered into an At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc.
• The company may issue and sell shares of its common stock, with an aggregate offering price of up to $5.1 million.
• Ladenburg will act as an agent or principal in the sale of these shares.
• The shares will be sold at market prices, and Ladenburg will receive a 3.0% cash commission on the gross sales proceeds.
• The company will also reimburse Ladenburg for certain expenses, including legal fees, up to $50,000 plus ongoing legal fees up to $7,500.
• The company is not obligated to sell any shares under the agreement, and either party can terminate the offering.
• The offering is made pursuant to a registration statement filed with the SEC.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It details a standard capital raising activity, which is generally positive for the company's financial position, but also carries the risk of dilution for existing shareholders.

Positives

• The at-the-market offering provides Calidi Biotherapeutics with a flexible way to raise capital.
• The company has the option to sell shares as needed, without being obligated to sell the full amount.
• The agreement allows for sales at market prices, potentially maximizing proceeds for the company.
• The offering is made under an existing registration statement, which streamlines the process.

Negatives

• The company will incur a 3.0% commission on the gross sales proceeds, reducing the net proceeds.
• The company will also incur additional expenses, including legal fees, up to $57,500.
• The offering could potentially dilute existing shareholders if the full amount of shares is sold.

Risks

• The company is not obligated to sell any shares, so there is no guarantee that the full $5.1 million will be raised.
• The market price of the shares could fluctuate, affecting the amount of capital raised.
• The offering could potentially dilute existing shareholders if the full amount of shares is sold.
• There is a risk that the offering could be terminated by either party.

Future Outlook

The company may, from time to time, issue and sell shares of its common stock through Ladenburg, but is not obligated to sell any shares under the agreement. The offering may be terminated by either the company or Ladenburg.

Industry Context

At-the-market offerings are a common method for companies, particularly in the biotech sector, to raise capital. This allows them to access funds without the need for a traditional underwritten offering, providing flexibility and potentially reducing dilution.

Comparison to Industry Standards

• At-the-market offerings are a common practice for companies of this size and stage, particularly in the biotech industry.
• The 3.0% commission rate is within the typical range for such offerings.
• The expense reimbursement terms are also standard for these types of agreements.
• Comparable companies that have used at-the-market offerings include XOMA Corporation and Agenus Inc.

Stakeholder Impact

• Shareholders may experience dilution if the full amount of shares is sold.
• The company will have access to additional capital, which could be used to fund operations and growth.
• The offering could potentially increase the company's visibility in the market.

Next Steps

• The company may begin selling shares of its common stock through Ladenburg.
• The company will file a prospectus supplement with the SEC in connection with the offering.
• The company will monitor market conditions and its capital needs to determine the timing and amount of shares to sell.

Key Dates

Keywords

at-the-market offering, common stock, capital raise, Ladenburg Thalmann, securities, equity financing, Calidi Biotherapeutics